Department of Radiation Oncology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
Department of Pathology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
Turk J Med Sci. 2019 Aug 8;49(4):1025-1032. doi: 10.3906/sag-1802-34.
BACKGROUND/AIM: This study aimed to describe the prognostic importance of epidermal growth factor (EGFR), phosphatase and tensin homolog (PTEN), human EGF receptor-2 (HER-2), and insulin-like growth factor 1 receptor (IGF-1R) in gastric cancer patients treated with postoperative chemoradiation therapy.
Sixty-nine patients treated with adjuvant chemoradiation therapy were retrospectively evaluated. Tumor samples were stained immunohistochemically.
All patients were treated with 3D conformal radiation therapy with concomitant and adjuvant chemotherapy. Perineural invasion (PNI) (P = 0.042), prechemoradiation therapy albumin levels below 3.5 mg/dL (P = 0.011), and EGFR positivity (P = 0.008) had negative effects on overall survival (OS). The median OS was 26 months for patients with PNI (+), 34.9 months for those with PNI (–), 19.5 months for those with albumin levels below 3.5 mg/dL, and 33.2 months for those with albumin levels above 3.5 mg/dL. IGF-1R (+) (P = 0.035) and history of cigarette smoking (P = 0.033) were observed to have a statistically significantly negative effect on disease-free survival (DFS). The median DFS was 29.2 months for IGF-1R (+) patients, 37.9 months for those with IGF-1R (-), and 26.3 and 40.59 months for smokers and nonsmokers, respectively.
IGF-1R and EGFR may be used for patient selection in future prospective studies that evaluate the prognostic importance of these receptors.
背景/目的：本研究旨在描述表皮生长因子（EGF）、磷酸酶和张力蛋白同系物（PTEN）、人类表皮生长因子受体-2（HER-2）和胰岛素样生长因子 1 受体（IGF-1R）在接受术后放化疗的胃癌患者中的预后意义。
回顾性评估了 69 例接受辅助放化疗的患者。肿瘤标本行免疫组织化学染色。
所有患者均接受 3D 适形放疗联合同期和辅助化疗。神经周围侵犯（PNI）（P=0.042）、放化疗前白蛋白水平低于 3.5mg/dL（P=0.011）和 EGFR 阳性（P=0.008）对总生存期（OS）有负面影响。PNI（+）患者的中位 OS 为 26 个月，PNI（-）患者为 34.9 个月，白蛋白水平低于 3.5mg/dL 的患者为 19.5 个月，白蛋白水平高于 3.5mg/dL 的患者为 33.2 个月。IGF-1R（+）（P=0.035）和吸烟史（P=0.033）被观察到对无病生存期（DFS）有统计学显著的负面影响。IGF-1R（+）患者的中位 DFS 为 29.2 个月，IGF-1R（-）患者为 37.9 个月，吸烟者和不吸烟者分别为 26.3 个月和 40.59 个月。
IGF-1R 和 EGFR 可用于未来评估这些受体预后意义的前瞻性研究中的患者选择。
